re Daily Mail13 Aug 2018 18:38
Extensive media coverage of Angle would not really serve any purpose at present as their route to market is defined by a sequence of milestones that need to be achieved first, rather than publicity.
They need FDA approval, KOL backed clinical and research data and commercial partners. Yes they are CE marked but FDA approval is crucial for complete validation of the Parsortix system.
MBC clinical data should be available in the Autumn followed by hopefully FDA approval next year.